Treatment of macroprolactinoma with cabergoline: A study of 85 patients

Clinical Endocrinology

Volumn 46, Issue 4, 1997, Pages 409-413

  Ferrari, C I ^a,i   Abs, R ^b   Bevan, J S ^c   Brabant, G ^d   Ciccarelli, E ^e   Motta, T ^f   Mucci, M ^g   Muratori, M ^f   Musatti, L ^g   Verbessem, G ^b   Scanlon, M F ^h  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g Sasol SpA   (Italy)

^h CARDIFF UNIVERSITY   (United Kingdom)

ⁱ Divisione di Medicina Generale 2   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; LISURIDE; METERGOLINE; PROLACTIN; QUINAGOLIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LIBIDO; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MENSTRUATION; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROLACTINOMA; TUMOR VOLUME; VERTIGO; VISUAL FIELD;

EID: 8244250765     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.1997.1300952.x     Document Type: Article

References (14)

1. Bevan, J.S., Webster, J., Burke, C.W. & Scanlon, M.F. (1992) Dopamine agonists and pituitary tumor shrinkage. Endocrine Reviews, 13, 220-240.
2. Caccavelli, L., Feron, F., Morange, I., Rouer, E., Benarous, R., Dewailly, D., Jaquet, P., Kordon, C. & Enjalabert, A. (1994) Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology, 60, 314-322.
3. Ciccarelli, E., Giusti, M., Miola, C., Potenzioni, F., Sghedoni, D., Camanni, F. & Giordano, G. (1989) Effectiveness and tolerability of long-term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients. Journal of Clinical Endocrinology and Metabolism, 69, 725-728.
4. Falsetti, L., Zanagnolo, V. & Galbignani, E. (1991) Cabergoline treatment in hyperprolactinemic women. Journal of Obstetrics and Gynecology, 11, 68-71.
5. Ferrari, C., Mattei, A., Melis, G.B., Paracchi, A., Muratori, M., Faglia, G., Sghedoni, D. & Crosignani, P.G. (1989) Cabergoline: long-acting oral treatment of hyperprolactinemic disorders. Journal of Clinical Endocrinology and Metabolism, 68, 1201-1206.
6. Ferrari, C., Paracchi, A., Mattei, A., De Vincentiis, S., D'Alberton, A. & Crosignani, P.G. (1992) Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinologica, 126, 489-494.
7. Ferrari, C., Piscitelli, G. & Crosignani, P.G. (1995) Cabergoline: a new drug for the treatment of hyperprolactinemia. Human Reproduction, 10, 101-107.
8. Jones, T.H. & Fraser, R.B. (1994) Cabergoline-treated hyperprolactinemia results in pregnancy in a bromocriptine-intolerant patient after seventeen years of infertility. British Journal of Obstetrics and Gynecology, 101, 349-350.
9. Melis, G.B., Gambacciani, M., Paoletti, A.M., Mais, V., Sghedoni, D. & Fioretti, P. (1989) Reduction in the size of prolactin-producing pituitary tumours after cabergoline administration. Fertility and Sterility, 52, 412-415.
10. Page, R.S. & Nussey, S.S. (1989) Cabergoline therapy of a large prolactinoma in a bromocriptine-intolerant patient. Journal of Obstetrics and Gynecology, 10, 156-158.
11. Razzaq, R., O'Halloran, D.J., Beardwell, C.G. & Shalet, S.M. (1993) The effects of CV 205-502 in patients with hyperprolactinemia intolerant and/or resistant to bromocriptine. Hormone Research, 39, 218-222.
12. Vilar, L. & Burke, C.W. (1994) Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine. Clinical Endocrinology, 41, 821-826.
13. Webster, J., Piscitelli, G., Polli, A., D'Alberton, A., Falsetti, L., Ferrari, C., Fioretti, P., Giordano, G., L'Hermite, M., Ciccarelli, E., Crosignani, P.G., DeCecco, L., Fadini, R., Faglia, G., Flamigni, C., Tamburrano, G., Ismail, I. & Scanlon, M.F. (1993) The efficacy and tolerability of long-term cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled, multicentre study. Clinical Endocrinology, 39, 323-329.
14. Webster, J., Piscitelli, G., Polli, A., Ferrari, C.I., Ismail, I. & Scanlon, M.F. (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. New England Journal of Medicine, 331, 904-909.